Showing 2641-2650 of 3223 results for "".
- Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials for Presbyopia Candidatehttps://modernod.com/news/orasis-pharmaceuticals-concludes-phase-3-clinical-trials-for-presbyopia-candidate/2480699/Orasis Pharmaceuticals announced the completion of its NEAR-1 and NEAR-2 phase 3 clinical studies. “Orasis is committed to reshaping vision possibilities by developing a presbyopia eye drop with the patient in mind,” said Elad Kedar, Chief Executive Officer of Orasis. &ldquo
- SECO International and National Academy of Opticianry Expand Partnership to Bring Optician-Focused Education to SECO 2023https://modernod.com/news/seco-international-and-national-academy-of-opticianry-expand-partnership-to-bring-optician-focused-education-to-seco-2023/2480695/SECO International announced that it has expanded a partnership with the National Academy of Opticianry (NAO) to bring a dedicated educational track for opticians to SECO 2023. The NAO, founded in 1963, represents opticians worldwide and is dedicated solely to education and training of all o
- EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-isabelle-lefebvre-as-chief-regulatory-officer/2480678/EyePoint Pharmaceuticals announced the appointment of Isabelle Lefebvre as Chief Regulatory Officer. Ms. Lefebvre brings more than 30 years of global regulatory affairs experience across all phases of drug development, including ophthalmic and ocular conditions. Ms. Lefebvre is su
- LumiThera Completes Acquisition of Diopsyshttps://modernod.com/news/lumithera-completes-acquisition-of-diopsys/2480675/LumiThera announced the completion of its acquisition of Diopsys, a provider of modern visual electrophysiology medical devices. Diopsys is now a wholly owned subsidiary of LumiThera. Financial terms the transaction were not disclosed. EyewireTV's covereage of the acq
- Phase 4 Study of Iluvien for DME Shows Statistically Significant Improvements in BCVA, CST, and Treatment Burden at 36 Monthshttps://modernod.com/news/phase-4-paladin-study-with-iluvien-published-in-peer-reviewed-journal-ophthalmology/2480659/Alimera Sciences announced that the 3-year results of the PALADIN study have been published in the peer-reviewed journal Ophthalmology. These study results show that patients with diabetic macular edema (DME) who received a single dose of the sustained release implant Iluv
- New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with Tepezza Comparable with Clinical Trial Observationshttps://modernod.com/news/new-post-marketing-safety-analysis-shows-rate-of-hearing-related-events-associated-with-tepezza-comparable-with-clinical-trial-observations/2480647/Horizon Therapeutics announced results from a new post-marketing safety analysis of hearing events associated with Tepezza for the treatment of Thyroid Eye Disease (TED). These findings, along with data on the sustainability of response to Tepezza, were presented at the 48th
- FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Wet AMD and DMEhttps://modernod.com/news/fda-approves-genentechs-vabysmo-the-first-bispecific-antibody-for-the-eye-to-treat-wet-amd-and-dme/2480603/The FDA has approved Genentech's Vabysmo (faricimab-svoa) for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME), marking the first bispecific antibody approved for the eye. Vabysmo is also the first and only FDA-approved inj
- The Vision Council Concludes Virtual Annual Business Meetinghttps://modernod.com/news/the-vision-council-concludes-virtual-annual-business-meeting/2480592/The Vision Council hosted its annual Business Meeting in a virtual format January 24. Presented under the banner of “It’s All Connected,” the meeting included a welcome address from Karen Roberts, The Vision Council’s Chair, followed by remarks from Ashley Mil
- Yehia Hashad, MD, to Join Bausch + Lomb as Executive Vice President of Research & Development and CMOhttps://modernod.com/news/yehia-hashad-md-will-join-bausch-lomb-as-executive-vice-president-of-research-development-and-cmo/2480581/Bausch Health Companies has announced that Yehia Hashad, MD, will join Bausch + Lomb as executive vice president of Research & Development and Chief Medical Officer (CMO), effective January 31, 2022. Dr. Hashad will join Bausch + Lomb from Allergan/AbbVie, where for the past 11
- Seoul Semiconductor Proves the Effect of SunLike Lighting on Myopia Improvementhttps://modernod.com/news/seoul-semiconductor-proves-the-effect-of-sunlike-lighting-on-myopia-improvement/2480573/Seoul Semiconductor announced that it has confirmed SunLike lighting’s effect on improving myopia, along with SERI_Singapore Eye Research Institute. In order to prove the correlation between health and SunLike, a natural lighting technology developed through years of R&D,